Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 50.15% is 44% above its 5-year average of 34.71%, near the high end of its 5-year range (26.68%–50.15%).
As of the fiscal period ended Tuesday, March 31, 2026. 37.42% above its 12-month average of 36.50%.
Reported quarterly profit margin; no daily interpolation.
NET PROFIT MARGIN
50.15%
NET PROFIT MARGIN AVG TTM
36.50%
NET PROFIT MARGIN AVG 3Y
34.70%
NET PROFIT MARGIN AVG 5Y
33.94%
NET PROFIT MARGIN AVG 10Y
33.78%
NET PROFIT MARGIN AVG 15Y
32.24%
NET PROFIT MARGIN AVG 20Y
29.59%
CURRENT VS TTM AVG
+37.42%
CURRENT VS 3Y AVG
+44.52%
CURRENT VS 5Y AVG
+47.75%
CURRENT VS 10Y AVG
+48.45%
CURRENT VS 15Y AVG
+55.54%
CURRENT VS 20Y AVG
+69.46%
SECTOR MEDIAN · HEALTHCARE
9.05%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+454.15%
vs the sector median at left
Novo Nordisk A/S
Market Cap
$195.30B
Net Profit Margin
50.15%
TTM Avg
36.50%
3Y Avg
34.70%
5Y Avg
33.94%
Market Cap
$182.63B
Net Profit Margin
11.65%
TTM Avg
23.34%
3Y Avg
19.20%
5Y Avg
17.71%
Market Cap
$210.78B
Net Profit Margin
15.06%
TTM Avg
14.95%
3Y Avg
14.84%
5Y Avg
16.47%
Market Cap
$163.96B
Net Profit Margin
30.99%
TTM Avg
15.29%
3Y Avg
17.07%
5Y Avg
15.27%
Market Cap
$241.25B
Net Profit Margin
17.02%
TTM Avg
15.23%
3Y Avg
12.72%
5Y Avg
10.53%
Market Cap
$138.59B
Net Profit Margin
15.95%
TTM Avg
15.52%
3Y Avg
19.51%
5Y Avg
19.37%
Market Cap
$134.91B
Net Profit Margin
18.87%
TTM Avg
-1.95%
3Y Avg
6.91%
5Y Avg
3.59%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $195.30B | 50.15% | 36.50% | 34.70% | 33.94% |
| Abbott Laboratories (ABT)vs › | $182.63B | 11.65% | 23.34% | 19.20% | 17.71% |
| Amgen Inc. (AMGN)vs › | $209.57B | 20.95% | 16.61% | 20.49% | 22.20% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $210.78B | 15.06% | 14.95% | 14.84% | 16.47% |
| Gilead Sciences, Inc. (GILD)vs › | $163.96B | 30.99% | 15.29% | 17.07% | 15.27% |
| AstraZeneca PLC (AZN)vs › | $241.25B | 17.02% | 15.23% | 12.72% | 10.53% |
| Pfizer Inc. (PFE)vs › | $144.85B | 11.83% | 12.51% | 14.97% | 18.18% |
| Danaher Corporation (DHR)vs › | $138.59B | 15.95% | 15.52% | 19.51% | 19.37% |
| Bristol-Myers Squibb Company (BMY)vs › | $134.91B | 18.87% | -1.95% | 6.91% | 3.59% |
| CVS Health Corp. (CVS)vs › | $132.98B | 0.72% | 0.84% | 1.34% | 1.79% |
Operating Margin
45.2%
Net Profit Margin
50.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 50.15% |
| 2025-12-31 | 33.98% |
| 2025-09-30 | 26.68% |
| 2025-06-30 | 34.48% |
| 2025-03-31 | 37.18% |
| 2024-12-31 | 32.95% |
| 2024-09-30 | 38.28% |
| 2024-06-30 | 29.46% |
| 2024-03-31 | 38.88% |
| 2023-12-31 | 33.35% |
| 2023-09-30 | 38.27% |
| 2023-06-30 | 35.78% |
| 2023-03-31 | 37.13% |
| 2022-12-31 | 28.26% |
| 2022-09-30 | 31.61% |
| 2022-06-30 | 32.27% |
| 2022-03-31 | 33.81% |
| 2021-12-31 | 28.41% |
| 2021-09-30 | 34.02% |
| 2021-06-30 | 36.69% |
| 2021-03-31 | 37.34% |
| 2020-12-31 | 28.99% |
| 2020-09-30 | 33.30% |
| 2020-06-30 | 35.41% |
| 2020-03-31 | 35.12% |
| 2019-12-31 | 26.89% |
| 2019-09-30 | 33.67% |
| 2019-06-30 | 31.94% |
| 2019-03-31 | 35.66% |
| 2018-12-31 | 28.58% |
| 2018-09-30 | 32.55% |
| 2018-06-30 | 37.74% |
| 2018-03-31 | 39.92% |
| 2017-12-31 | 29.48% |
| 2017-09-30 | 36.71% |
| 2017-06-30 | 34.75% |
| 2017-03-31 | 35.70% |
| 2016-12-31 | 29.42% |
| 2016-09-30 | 35.60% |
| 2016-06-30 | 36.30% |
| 2016-03-31 | 34.75% |
| 2015-12-31 | 28.60% |
| 2015-09-30 | 31.29% |
| 2015-06-30 | 30.83% |
| 2015-03-31 | 39.19% |
| 2014-12-31 | 26.56% |
| 2014-09-30 | 29.21% |
| 2014-06-30 | 32.34% |
| 2014-03-31 | 31.75% |
| 2013-12-31 | 27.90% |
| 2013-09-30 | 31.28% |
| 2013-06-30 | 31.50% |
| 2013-03-31 | 29.94% |
| 2012-12-31 | 27.45% |
| 2012-09-30 | 28.56% |
| 2012-06-30 | 27.46% |
| 2012-03-31 | 26.27% |
| 2011-12-31 | 25.88% |
| 2011-09-30 | 25.41% |
| 2011-06-30 | 25.84% |
| 2011-03-31 | 25.95% |
| 2010-12-31 | 24.47% |
| 2010-09-30 | 23.00% |
| 2010-06-30 | 23.05% |
| 2010-03-31 | 24.31% |
| 2009-12-31 | 17.78% |
| 2009-09-30 | 22.01% |
| 2009-06-30 | 23.01% |
| 2009-03-31 | 21.60% |
| 2008-12-31 | 18.54% |
| 2008-09-30 | 23.69% |
| 2008-06-30 | 22.26% |
| 2008-03-31 | 20.54% |
| 2007-12-31 | 9.02% |
| 2007-09-30 | 20.80% |
| 2007-06-30 | 34.57% |
| 2007-03-31 | 17.40% |
| 2006-12-31 | 16.44% |
| 2006-09-30 | 18.53% |
| 2006-06-30 | 17.94% |
| 2006-03-31 | 13.55% |
| 2005-12-31 | 12.68% |
| 2005-09-30 | 19.90% |
| 2005-06-30 | 20.31% |
| 2005-03-31 | 16.93% |
| 2004-12-31 | 18.00% |
| 2004-09-30 | 16.59% |
| 2004-06-30 | 17.77% |
| 2004-03-31 | 16.39% |
| 2003-12-31 | 18.78% |
| 2003-09-30 | 16.89% |
| 2003-06-30 | 19.72% |
| 2003-03-31 | 17.86% |
| 2002-12-31 | 17.44% |
| 2002-09-30 | 15.52% |
| 2002-06-30 | 16.01% |
